- Home
- CRIS vs LSTA Comparison
CRIS vs LSTA Comparison
Compare CRIS & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRIS | LSTA |
|---|---|---|
| Founded | 2000 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 20.9M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRIS | LSTA |
|---|---|---|
| Price | $1.16 | $2.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $16.50 | ★ $23.50 |
| AVG Volume (30 Days) | ★ 115.6K | 23.4K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,650,000.00 | $1,070,000.00 |
| Revenue This Year | $6.13 | N/A |
| Revenue Next Year | $8.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.56 | N/A |
| 52 Week Low | $1.02 | $1.81 |
| 52 Week High | $4.50 | $4.20 |
Technical Indicators
Market Signals| Indicator | CRIS | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 42.23 | 50.24 |
| Support Level | $1.15 | $1.97 |
| Resistance Level | $1.41 | $2.15 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 15.80 | 73.00 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.